Company Overview and News

2
John's April Dividend Income Tracker - Retirement Accounts

2018-05-21 seekingalpha
This is the second month I have officially tracked dividend income (in an article) for John's Traditional and Roth IRA Accounts. His combined dividend income totaled $1789.12.

 
Retirement Security: How To Navigate Market Volatility

2018-05-19 seekingalpha
Has the return of volatility the last three months have you wondering how best to deal with it?

3
Joseph To Pharaoh: Save Surplus Grain For Inevitable Droughts And Famine

2018-05-12 seekingalpha
More than that, investing your surplus in stalwarts like AT&T will see you through both the droughts and famines.

 
7 Stocks Paying Monthly Dividends That You Should Consider Buying

2018-05-12 investorplace
Nowadays, it seems like a lot of stocks want to become monthly dividend stocks. The granddaddy of monthly dividend stocks is Realty Income Corp (NYSE:O). In fact, it even has a registered trademark: “The Monthly Dividend Company”.

 
LTC / LTC Properties, Inc. DEFA14A

2018-05-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
LTC Properties Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-11 seekingalpha
The following slide deck was published by LTC Properties Inc. in conjunction with their 2018 Q1 earnings call.

 
LTC Properties' (LTC) CEO Wendy Simpson on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good morning and welcome to the LTC Properties First Quarter 2018 Results Conference Call. [Operator Instructions]

 
LTC / LTC Properties, Inc. 8-K (Current Report)

2018-05-09 sec.gov
UNITED STATES

 
LTC / LTC Properties, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
ltc_Current folio_10Q Table of Contents

 
4 of the Best REITs to Buy Now | InvestorPlace

2018-05-09 investorplace
Technological change and demographic shifts have seemingly touched every industry in one form or another. Real estate is no exception, and some of the best real estate investment trusts (REITs) to buy now touch upon these shifts. They have seen monumental shifts that have led to the ascendancy or decline in certain types of REITs.

 
John And Jane - April Dividend Income Tracker - Taxable Account

2018-05-08 seekingalpha
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.

 
BRIEF-LTC Sells Portfolio Of Six Assisted Living And Memory Care Communities For $67.5 Mln

2018-05-01 reuters
* PRESS RELEASE - LTC SELLS PORTFOLIO OF SIX ASSISTED LIVING AND MEMORY CARE COMMUNITIES FOR $67.5 MILLION

 
Recent Stock Purchase April 2018

2018-04-25 seekingalpha
I can't believe it's been over a month since my last buy was made, but if you have been following my blog for some time, you know at least one buy is coming every calendar month. With one week left in April, I decided to deploy some fresh capital into a market that has been very, very generous as of late in terms of giving us much better buying opportunities in many "name brand" stocks that have been previously deemed untouchable because of low yields, high valuations and relatively speaking, high prices.

 
LTC / LTC Properties, Inc. DEF 14A

2018-04-24 sec.gov
ltc_Current Folio_DEF14A Table of Contents

 
Sabra: A Healthcare REIT With Tailwinds And A 10.5% Dividend

2018-04-23 seekingalpha
Sabra Healthcare Inc. (SBRA) has had its stock price beaten down along with other healthcare real estate companies over the last four months. Many investors do not want to bother with such a laggard. For those up to the challenge, here is a look under the hood.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 502175102